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We used a murine model of acute, posttraumatic osteomyelitis to evaluate the virulence of two divergent Staphylococcus aureus
clinical isolates (the USA300 strain LAC and the USA200 strain UAMS-1) and their isogenic sarAmutants. The results confirmed
that both strains caused comparable degrees of osteolysis and reactive new bone formation in the acute phase of osteomyelitis.
Conditionedmedium (CM) from stationary-phase cultures of both strains was cytotoxic to cells of established cell lines
(MC3TC-E1 and RAW 264.7 cells), primary murine calvarial osteoblasts, and bone marrow-derived osteoclasts. Both the cyto-
toxicity of CM and the reactive changes in bone were significantly reduced in the isogenic sarAmutants. These results confirm
that sarA is required for the production and/or accumulation of extracellular virulence factors that limit osteoblast and oste-
oclast viability and that thereby promote bone destruction and reactive bone formation during the acute phase of S. aureus os-
teomyelitis. Proteomic analysis confirmed the reduced accumulation of multiple extracellular proteins in the LAC and UAMS-1
sarAmutants. Included among these were the alpha class of phenol-soluble modulins (PSMs), which were previously implicated
as important determinants of osteoblast cytotoxicity and bone destruction and repair processes in osteomyelitis. Mutation of the
corresponding operon reduced the cytotoxicity of CM from both UAMS-1 and LAC cultures for osteoblasts and osteoclasts. It
also significantly reduced both reactive bone formation and cortical bone destruction by CM from LAC cultures. However, this
was not true for CM from cultures of a UAMS-1 psmmutant, thereby suggesting the involvement of additional virulence factors
in such strains that remain to be identified.
Staphylococcus aureus is a highly versatile pathogen capable ofcausing a remarkable array of human infections. One of the
most devastating of these is osteomyelitis, which is extremely dif-
ficult to eradicate without extensive and often repetitive surgical
debridement (1). Indeed, it has been suggested that, as with can-
cer, “remission” is a more appropriate term than “cure” in the
context of osteomyelitis (2). Several factors contribute to this ther-
apeutic recalcitrance, including the inability to diagnose the infec-
tion before it has progressed to a chronic stage in which the local
vasculature is compromised, the formation of a bacterial biofilm
that limits the efficacy of both conventional antibiotics and host
defenses, the emergence of phenotypic variants within the biofilm
(persister cells and small-colony variants) that exhibit metabolic
traits that limit their antibiotic susceptibility, and the ability of the
pathogens involved, including S. aureus, to invade and replicate
within host cells, including osteoblasts (3–9). Collectively, these
factors dictate that the clinical problem of osteomyelitis extends
far beyond acquired resistance and the increasingly limited avail-
ability of effective antibiotics.
Our laboratories have placed amajor emphasis on overcoming
this problemby exploring alternativemeans for early diagnosis (3,
10), developing improved methods for localized antibiotic deliv-
ery for the prevention and treatment of infection (11–14), and
identifying the bacterial factors that contribute to the prominence
of S. aureus as an orthopedic pathogen. With respect to the last
area of exploration, our studies have led us to place a primary
emphasis on the staphylococcal accessory regulator (sarA), muta-
tion of which limits biofilm formation to a greater degree than
mutation of any other regulatory locus thatwe have examined (11,
15). The negative impact of mutated sarA on biofilm formation is
also apparent in all S. aureus strains that we have examined, other
than those with recognized regulatory defects (16, 17). Moreover,
even in those cases in which a mutation enhanced biofilm forma-
tion, concomitant mutation of sarA reversed this effect (12, 15–
17). We also confirmed that the limited ability of sarAmutants to
form a biofilm can be correlated with increased susceptibility to
diverse functional classes of antibiotics in vivo (18, 19). Addition-
ally, mutation of sarA limits the ability of S. aureus to persist in the
bloodstream and cause secondary infections, including hematog-
enous osteomyelitis (20, 21).
Taken together, these results suggest that sarA is a viable and
perhaps preferred regulatory target in the context of biofilm-as-
sociated infections, including osteomyelitis. However, this con-
clusion must be interpreted with caution. For instance, under in
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vitro conditions, the relative impact of sarA versus that of the
saePQRS (saeRS) regulatory locus on biofilm formation was re-
cently shown to be dependent on the medium used to carry out
the biofilm assay (22). Moreover, mutation of saeRS in the
USA300 strain LAC was shown to limit virulence in a murine
model of posttraumatic osteomyelitis owing to the increased pro-
duction of the extracellular protease aureolysin, which results in
the decreased accumulation of phenol-soluble modulins (PSMs)
that would otherwise promote cytotoxicity for osteoblasts and
bone destruction (23). A recent report also demonstrated that,
under the hypoxic conditions encountered in bone, particularly as
the infection progresses to a point that compromises the local
blood supply, the srrAB regulatory locus plays a key role in S.
aureus survival (24). Such results emphasize the complexity of the
disease process in osteomyelitis and the fact that biofilm forma-
tion per se is not the only relevant consideration.
In this respect, it is important to note that the impact of mu-
tating sarAhas not been evaluated in the context of bone infection.
It has been demonstrated that, at least under in vitro conditions,
mutation of sarA results in a much greater increase in protease
production than mutation of saeRS (12, 17) and that this can be
correlated with the reduced accumulation of multiple virulence
factors, including PSMs (20). Thus, it would be anticipated that
mutation of sarAwould also have a significant impact in this clin-
ical context, but this has not been experimentally determined.
Additionally, studies examining the role of different regulatory
loci in a newly developed murine model of posttraumatic osteo-
myelitis have been limited to date to the USA300 strain LAC,
which produces PSMs at high levels by comparison tomany other
strains of S. aureus (25–27). In this report, we address these issues
by using the samemurine model to assess the relative virulence of
two genetically and phenotypically divergent strains of S. aureus
and their isogenic sarA and psm mutants.
MATERIALS AND METHODS
Bacterial strains and growth conditions. The S. aureus strains utilized in
this study included a plasmid-cured, erythromycin-sensitive derivative of
methicillin-resistant S. aureus (MRSA) USA300 strain LAC (28), USA200
methicillin-sensitive S. aureus osteomyelitis isolate UAMS-1 (29), and
derivatives of each carryingmutations in sarA or the operon encoding the
alpha class of PSMs (PSMs). Mutants were generated by phage 11-
mediated transduction from mutants already on hand (19, 20, 23). Mu-
tations in sarA and the psm operonwere genetically complemented using
pSARA and pTX as previously described (16, 27). Strains were main-
tained at 80°C in tryptic soy broth (TSB) containing 25% (vol/vol)
glycerol. For analysis, strains were cultured from cold storage by plating
on tryptic soy agar (TSA) with selection with the appropriate antibiotic.
The following antibiotics were used at the indicated concentrations:
chloramphenicol (Cm), 10 g ml1; erythromycin (Erm), 10 g ml1;
kanamycin (Kan), 50 g ml1; neomycin (Neo), 50 g/ml; and tetracy-
cline (Tet), 5 g ml1.
Preparation of conditionedmedium. Stationary-phase cultures were
standardized to an optical density at 560 nmof 8.0. Cells were harvested by
centrifugation, and the supernatants were filter sterilized. The culture
medium was combined 1:1 with the appropriate cell culture medium
containing 10% fetal bovine serum (FBS) and added to cell monolayers
for cytotoxicity assays.
Cultivation of primary murine calvarial osteoblasts. Murine pri-
mary calvarial osteoblasts were obtained from 3- to 5-day-old C57BL/6
mouse pups according to standard procedures (30), modified as follows:
whole calvariae were dissected (the periosteum and endosteum were
scraped off with a scalpel) and sequentially digested for 20 min at 37°C in
alphaminimal essentialmedium (alpha-MEM) containing 0.1mg/ml col-
lagenase P (Roche), 0.04% trypsin-EDTA, and penicillin-streptomycin
(166U/ml and 166g/ml, respectively). The first 2 fractions of cells were
discarded. Calvariae were further diced with sterile surgical scissors
and digested in 1 ml of alpha-MEM with a double amount of collage-
nase and trypsin-EDTA for 1 h at 37°C with vigorous shaking every 15
to 20 min. Then, 3.75 ml of alpha-MEM containing 15% FBS and
penicillin-streptomycin was added. After 24 h, the osteoblasts were
washed with sterile phosphate-buffered saline (PBS) and expanded
alpha-MEM containing 10% FBS, 2 mM glutamine, and penicillin and
streptomycin (100 g/ml and 100 g/ml, respectively) for 2 to 4 days
before passaging. Only early-passage osteoblasts grown in culture me-
dium supplemented with 100 g/ml of ascorbic acid were used for
cytotoxicity assays.
Cytotoxicity assay. Cytotoxicity assays with primary osteoblasts and
established cell lines were done using the methods described above.
MC3T3-E1 and RAW 264.7 cells were obtained from the American Type
Culture Collection (ATCC) and propagated according to ATCC recom-
mendations. Cells were grown at 37°C in 5%CO2with the replacement of
medium every 2 or 3 days. For cytotoxicity assays, cells were seeded into
black clear-bottom 96-well tissue culture-grade plates at a density of
10,000 cells per well for MC3T3-E1 cells, 50,000 cells per well for RAW
264.7 cells, or 10,000 cells per well for calvarial osteoblasts. After 24 h, the
growthmediumwas removed and replacedwithmedium containing a 1:1
ratio of cell culture complete growth medium and S. aureus conditioned
medium. The monolayers were incubated for an additional 24 h prior to
removal of the medium and assessment of cell viability using calcein-AM
to stain live cells (Thermo Fisher Scientific) according to themanufactur-
er’s specifications. An Omega FLUOstar microplate reader (BMG
Labtech) was used to determine the fluorescent intensity at 517 nm. The
results of themicrotiter plate assays were confirmed through fluorescence
microscopy.
Cultivation and TRAP staining of primary osteoclasts.Whole bone
marrow was extracted from the tibia and femurs of one or two 8- to
10-week-old mice. Red blood cells were lysed in buffer (150 mM
NH4Cl, 10 mM KNCO3, 0.1 mM EDTA, pH 7.4) for 5 min at room
temperature. Bone marrow cells (5  106) were plated in a 100-mm
petri dish and cultured in alpha-10 medium (alpha-MEM, 10% heat-
inactivated FBS, and PSG [100 U/liter penicillin, 0.1 mg/liter strepto-
mycin, and 2 mM L-glutamine]) containing 1/10 volume of condi-
tioned medium (CM) supernatant from CMG 14-12 cells containing
recombinant macrophage colony-stimulating factor (M-CSF) at 1
g/ml for 4 to 5 days. Preosteoclasts and osteoclasts were generated by
culturing bone marrow macrophages (BMMs) at a density of 160
BMMs/mm2 in 1/100 vol of CMG 14-12 culture supernatant and 100
ng/ml of recombinant RANKL. To determine cell viability, tartrate-
resistant acid phosphatase (TRAP) staining was used to count the vi-
able cells. BMMs were cultured on a 48-well tissue culture plate in
alpha-10 medium with M-CSF and RANKL for 4 to 5 days. After me-
dium replacement, the cells were treated with S. aureus culture super-
natants diluted 1:1 in complete growthmedium. The cells were then fixed
with 4%paraformaldehyde–PBS andTRAP stainedwithNaK tartrate and
naphthol AS-BI phosphoric acid (Sigma-Aldrich).
Murine model of acute posttraumatic osteomyelitis. The murine
model of acute posttraumatic osteomyelitis model was performed as pre-
viously described (23). Briefly, surgery was performed on the right hind
limb of 8- to 10-week-old female C57BL/6 mice. Prior to surgery, the
mice received 0.1 mg/kg of body weight buprenorphine via subcuta-
neous injection. Anesthesia was then maintained using isoflurane. The
femur was exposed by blunt dissection, and a 1-mm unicortical bone
defect was created at the lateral midshaft of the femur with a 21-gauge
Precision Glide needle (Becton Dickinson). A bacterial inoculum of
1  105 CFU in 2 l was delivered into the intramedullary canal. The
muscle fasciae and skin were then closed with sutures, and the mice
were allowed to recover from anesthesia. Infection was allowed to
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proceed for 14 days, at which time the mice were euthanized and the
right femur was removed and subjected to micro-computed tomogra-
phy (micro-CT) analysis. All experiments involving animals were re-
viewed and approved by the Institutional Animal Care and Use Com-
mittee of the University of Arkansas for Medical Sciences and were
performed according to NIH guidelines, the Animal Welfare Act, and
U.S. federal law.
Micro-computed tomography. The analysis of cortical bone destruc-
tion and new bone formation was performed using micro-CT imaging
with a Skyscan 1174 micro-CT (Bruker), and scans were analyzed using
the manufacturer’s analytical software. Briefly, axial images of each femur
were acquired at a resolution of 6.7 m at 50 kV and 800 A through a
0.25-mmaluminumfilter. Bones were visualized using a scout scan and then
scanned in three sections as an oversize scan to image the entire femoral
length. The volume of cortical bone was isolated in a semiautomated process
per the manufacturer’s instruction. Briefly, cortical bone was isolated from
soft tissueand thebackgroundbyglobal thresholding (lowthreshold, 89;high
threshold, 255). The processes of opening, closing, dilation, erosion, and
despeckling were configured using the bones from sham-treated controls to
separate the new bone from the existing cortical bone, and a task list was
created to apply the same process and values to all bones in the data set. After
processing of the bones using the task list, the volume of interest (VOI) was
correctedbydrawing inclusiveor exclusive contourson theperiosteal surface.
Cortical bone destruction analysis consisted of 600 slices centered on the
initial surgical bone defect.Destructionwas determined by subtraction of the
volume of infected bones from the average bone volume from sham-treated
controls. Reactive new bone formation was assessed by first isolating the re-
gion of interest (ROI) that contained only the original cortical bone (as de-
scribed above). After cortical bone isolation the new bone volumewas deter-
mined by subtraction of the original bone volume from the total bone
volume. All calculations were performed on the basis of direct voxel counts.
Proteomic analysis. Assessment of the secreted proteome of both S.
aureus parent strains and their isogenic sarA mutants was performed in
triplicate as previously described (20). Briefly, the lanes of SDS-polyacryl-
amide gels were divided into 20 slices and subjected to in-gel trypsin
digestion. The gel slices were destained in 50% methanol, 100 mM am-
monium bicarbonate, followed by reduction in 10 mM Tris(2-carboxy-
ethyl)phosphine and alkylation in 50 mM iodoacetamide. The gel slices
were then dehydrated in acetonitrile, followed by addition of 100 ng of
sequencing-grade porcine trypsin (Promega, Madison, WI) in 100 mM
ammonium bicarbonate and incubation at 37°C for 12 to 16 h. The pep-
tide products were then acidified in 0.1% formic acid (Fluka, Milwaukee,
WI). Tryptic peptides were analyzed by high-resolution tandem mass
spectrometry (MS/MS) with a Thermo LTQ Orbitrap Velos mass spec-
trometer coupled to a Waters nanoAcquity liquid chromatography (LC)
system. The proteins were identified from the MS/MS spectra by search-
ing the UniprotKB USA300 (LAC) or MRSA252 (UAMS-1) database for
the organism Staphylococcus aureus (2,607 entries) using the Mascot
search engine (Matrix Science, Boston, MA).
Statistical analysis.The results of both in vitro and in vivo experiments
were tested for statistical significance using the Student t test. Compari-
sons were made between the two parent strains or between each parent
strain and its appropriate isogenic mutant. P values of 0.05 were con-
sidered statistically significant.
RESULTS AND DISCUSSION
A primary focus of our laboratories has been on developing alter-
native strategies that can be used to overcome the therapeutic
recalcitrance of orthopedic infections, including osteomyelitis.
Despite the current prominence of hypervirulent isolates of the
USA300 clonal lineage (25), it is imperative that the genetic and
phenotypic diversity of different S. aureus strains be taken into
account in this regard. Based on this, we chose to focus on the
USA300 methicillin-resistant strain LAC and the USA200 methi-
cillin-sensitive isolate UAMS-1, which have been shown to be dis-
tinct with respect to both gene content and overall transcriptional
patterns by comparison to each other (29, 31). Of note is the fact
that LAC and many other USA300 isolates express the acces-
sory gene regulator (agr) at higher levels than strains like
UAMS-1 and, consequently, produce extracellular toxins, in-
cluding phenol-soluble modulins (PSMs), at higher levels (25,
27). At the same time, UAMS-1 (ATCC 49230) has a proven
clinical provenance in the specific context of osteomyelitis,
having been isolated directly from the bone of a patient during
surgical debridement (32).
Thus, we used equivalent numbers (105 CFU) of LAC, UAMS-1,
and their isogenic sarA mutants to infect mice via direct inocula-
tion into the medullary canal via a unicortical defect (23). Femurs
were harvested at 14 days postinfection and subjected to mi-
cro-CT analysis to assess cortical bone destruction and reactive
new bone (callus) formation. Quantitative analysis was based on
reconstructive evaluation of a series of images spanning from the
prominence of the lessor trochanter to the distal femoral growth
plate. This analysis confirmed that infection with either strain
caused osteolysis at and around the site of inoculation and reactive
new bone (callus) formation both proximally and distally to this
site (Fig. 1). The prevalence of both of these phenotypes was ele-
vated in mice infected with LAC by comparison to those infected
with UAMS-1, although these differences were not statistically
significant (Fig. 2).
In LAC, mutation of sarA limited both osteolysis and reactive
new bone formation to a significant degree by comparison to
those in the isogenic parent strain (Fig. 2). InUAMS-1, the impact
of mutating sarAwas statistically significant only in the context of
reactive bone formation, with cortical bone destruction being re-
duced, but not to a significant degree. However, these resultsmust
be interpreted with caution, in that the surgical procedure itself
involves the destruction of cortical bone to gain access to the in-
tramedullary canal, thus complicating the analysis by comparison
to that involving new bone formation.
FIG 1 Bone destruction and reactive bone formation in osteomyelitis as a
function of sarA. C57BL/6 mice (n  5) were infected with LAC, UAMS-1
(U1), or their isogenic sarAmutants (sarA). Femurswere harvested at 14 days
after inoculation and subjected to micro-CT imaging analysis. Anteroposte-
rior views of infected femurs are shown for comparison. Sham, results formice
subjected to the surgical procedure and injected with sterile PBS.
Loughran et al.
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Nevertheless, these results suggest that the virulence factor(s)
produced by S. aureus that contributes to bone remodeling in
osteomyelitis is likely produced in larger amounts by LAC than
UAMS-1 and that mutation of sarA limits the production and/or
accumulation of these virulence factors in both strains. Thus,
while mutation of sarA has been shown to limit biofilm forma-
tion both in vitro and in vivo to a degree that can be correlated
with increased antibiotic susceptibility (15, 18, 19, 33) and to
limit virulence in a murine model of bacteremia that can be
correlated with a reduced capacity to cause hematogenous os-
teomyelitis (20, 21), this is the first demonstration that it also
limits virulence in a relevant model of posttraumatic bone in-
fection and, perhaps more importantly, that it does so in di-
verse clinical isolates.
Bone is a highly dynamic physiological environment in which
constant remodeling occurs in response to biomechanical stresses
and hormonal influences (34, 35). This remodeling process is me-
diated by osteoblasts and osteoclasts, with the first being respon-
sible for new bone formation (ossification) and the second being
responsible for bone resorption prior to osteoblast-mediated os-
sification. Osteocytes are terminally differentiated osteoblasts that
become embeddedwithin lacunae in themineralized bonematrix;
they extend long cytoplasmic processes through apertures of the
lacunae that form a dense canalicular network inside the bone.
They are the most abundant cell type in the adult skeleton and
form an interconnected network that can coordinate the activity
of osteoblasts and osteoclasts to facilitate bone repair and ulti-
mately maintain its structural integrity (34, 35). Thus, disruption
in the balance of osteoblast versus osteoclast function has the po-
tential to compromise this integrity. For instance, bone destruc-
tion could result from increased osteoclast function or decreased
osteoblast function. Conversely, new bone (callus) formation in
the form of woven bone could result from increased osteoblast
function or decreased osteoclast function.
To investigate whether osteoblasts and osteoclasts are directly
affected by the secreted products of S. aureus, we evaluated the
extent to which conditionedmedium (CM) from cultures of LAC,
UAMS-1, and their isogenic sarA mutants impact osteoblast and
osteoclast viability. We chose to focus on CM based on a previous
report demonstrating that the increased production of extracellu-
lar proteases in a LAC saeRS mutant limits the accumulation of
important extracellular virulence factors that contribute to the
bone destruction and repair process (23) and our studies demon-
strating that mutation of sarA results in a greater increase in pro-
tease production than mutation of saeRS (12, 17). We initially
focused on the preosteoblast cell line MC3T3-E1 because these
cells have characteristics similar to those of primary calvarial os-
teoblasts and are derived from C57BL/6 mice, which is the same
mouse strain used for our in vivo experiments. Similarly, we used
the RAW 264.7 macrophage cell line as a surrogate for osteoclasts
because they exhibit characteristics similar to those of bone mar-
rowmacrophages, the precursors of primary osteoclasts, but as an
established cell line offered the advantage of ready accessibility
and ease of manipulation.
CM from LAC (Fig. 3) and UAMS-1 (Fig. 4) cultures was cyto-
toxic for both MC3T3-E1 and RAW 264.7 cells, and in both strains,
mutationof sarA limited this cytotoxicity.Thiswasalso truewhen the
experimentswere repeatedusingprimarycalvarialosteoblasts (Fig.5)
and when the results were assessed on the basis of the number of
TRAP-positive multinucleated, primary bone marrow-derived oste-
oclasts (Fig. 6). When the results were assessed using primary oste-
oclasts, CM from LAC cultures appeared to be more cytotoxic for
primarybonemarrow-derivedmacrophages, although thedifference
did not reach statistical significance. The changes observedwith each
parent strainand its isogenic sarAmutantswereconsistentwhenboth
established cell lines and primary cells were used, and this finding is
important, given that cell lines aremuch easier tomaintain andmore
amenable to use in experiments. More importantly, these results are
also consistent with the hypothesis that there is a cause-and-effect
relationship between osteoblast and osteoclast cytotoxicity and
bone destruction and repair processes in acute, posttraumatic osteo-
myelitis.
Given the cytotoxicity of CM from both LAC and UAMS-1
cultures for osteoblasts and osteoclasts and the impact of both
strains on bone destruction and repair processes, we examined the
exoprotein profiles of each strain and their isogenic sarAmutants
by in-gel tryptic digestion followed by GeLC-MS/MS. These stud-
ies revealed global differences between both LAC and UAMS-1
and their isogenic sarAmutants (see Table S1 in the supplemental
material). A draft genome sequence of UAMS-1 has been pub-
lished (36), but a fully annotated protein database is not yet avail-
able. Thus, on the basis of our studies demonstrating that they are
closely related strains (31), identification of UAMS-1 proteins was
based on comparisons toMRSA252 proteins. However, it should be
noted that while these two strains are closely related, they are not
identical. For instance, theMRSA252 genome, like that of LAC, does
not encode the toxic shock syndrome toxin 1 (TSST-1) gene (tst),
which is present in UAMS-1 (31).
Nevertheless, several particularly notable differences between
LAC and UAMS-1 were identified (Table 1). For instance, the
analyses confirmed that, unlike LAC, UAMS-1 does not produce
LukD/LukE, the Panton-Valentine leucocidin (PVL), or alpha
toxin, all of which are potentially important virulence factors in
the phenotypes that we observed. However, LukD was present in
increased amounts in a LAC sarAmutant relative to the amounts
in its parent strain, while LukE was detected at very low levels in
both strains (Table 1). Similarly, PVLwas also present in increased
amounts in a LAC sarA mutant relative to the amounts in its
isogenic parent strain. This suggests that LukD/LukE or PVL is
unlikely to contribute to the attenuation of a LAC sarAmutant. In
contrast, alpha toxin was present in dramatically reduced
amounts in a LAC sarA mutant (at 	11% of the amount in the
isogenic parent strain). This suggests that alpha toxin could con-
FIG 2 Quantitative analysis of micro-CT imaging. Images were analyzed for
reactive new bone (callus) formation and cortical bone destruction in mice
infected with LAC, UAMS-1 (U1), or their isogenic sarA mutants (sarA).
Sham, results of the same analysis with mice subjected to the surgical proce-
dure and injected with sterile PBS. *, statistical significance compared to the
results of sham treatment; **, statistical significance compared to the results
for the isogenic parent strain.
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tribute to both the enhanced virulence of LAC relative to that of
UAMS-1 and the reduced virulence of a LAC sarA mutant (24).
However, given its absence in UAMS-1, alpha toxin clearly does
not contribute to the cytotoxicity or bone remodeling that we
observed with this strain.
In general, these proteomics studies also confirmed the find-
ings of our previous experiments (26) demonstrating that PSMs,
specifically, the alpha class of PSMs (PSMs), are present in in-
creased levels in LAC relative to UAMS-1 and at reduced levels in
both LAC and UAMS-1 sarA mutants relative to the levels in the
FIG 3 Cytotoxicity of LAC assessed using established cell lines. MC3T3-E1 or RAW 264.7 cells were exposed to CM from cultures of LAC, its sarA mutant
(sarA), and its complemented sarA mutant (sarAC). Viability was assessed after 24 h using Invitrogen Live calcein-AM staining (top) or fluorescence
microscopy (bottom). The results of calcein-AM staining are reported as the average mean fluorescence intensity (MFI) 
 standard deviation. *, statistical
significance compared to the results observed with the isogenic parent strain; **, statistical significance compared to the results observed with the isogenic sarA
mutant. DMEM, Dulbecco modified Eagle medium.
FIG4 Cytotoxicity ofUAMS-1 assessedusing established cell lines.MC3T3-E1orRAW264.7 cellswere exposed toCMfromcultures ofUAMS-1 (U1), its sarAmutant
(sarA), and its complemented sarA mutant (sarAC). Viability was assessed after 24 h using Invitrogen Live calcein-AM staining (top) or fluorescence microscopy
(bottom). The results of calcein-AMstaining are reported as the averagemean fluorescence intensity (MFI)
 standard deviation. *, statistical significance compared to
the results observed with the isogenic parent strain; **, statistical significance compared to the results observed with the isogenic sarAmutant.
Loughran et al.
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isogenic parent strains (Fig. 7 and Table 1). In fact, inUAMS-1 the
amounts of 2PSM and 3PSMwere below the limit of detection
of the assay. Nevertheless, the differences observed between
UAMS-1 and its sarAmutant did reach statistical significancewith
respect to 1PSM and 4PSM, and statistically significant differ-
ences were observed between LAC and its sarA mutant with re-
spect to allPSMs (Fig. 7 andTable 1). These results are consistent
with the results of our previous experiments, in which PSM levels
were measured directly by high-pressure liquid chromatography
(26). Moreover, previous studies employing a mutagenesis ap-
proach in LAC implicated PSMs as key factors contributing to
osteoblast cytotoxicity and bone remodeling in the same murine
model that we employed in the experiments whose results are
reported here (23).
Based on this, we examined the extent to which these peptides
contribute to the phenotypes that we observed in each parent
strain. In both LAC and UAMS-1, mutation of the operon encod-
ing PSMs resulted in a significant decrease in cytotoxicity for both
MC3T3-E1 cells andRAW264.7 cells (Fig. 8). This effect appeared to
be greater for LAC than for UAMS-1, particularly when it was as-
sessed using MC3T3-E1 cells. The cytotoxicity of both LAC and
UAMS-1 PSMmutants was also significantly reduced when it was
assessed using primary osteoblasts and osteoclasts, and when it was
assessed using calvarial osteoblasts, the impact of eliminating PSM
production was significantly greater for LAC than for UAMS-1 (Fig.
9).This is consistentwith theobservation thatLACproducesPSMsat
higher levels than UAMS-1 (26). Nevertheless, these results demon-
strate that PSMs play an important role in mediating osteoblast and
osteoclast cytotoxicity even in a strain like UAMS-1 that produces
PSMs at relatively low levels, and they suggest that the reduced accu-
FIG 5 Cytotoxicity of conditioned medium for primary osteoblasts. Primary osteoblast cells were exposed to conditioned CM from cultures of the indicated
strains, and viability was assessed after 24 h using Invitrogen Live calcein-AM staining (top) or fluorescence microscopy (bottom). The results of calcein-AM
staining are reported as the average mean fluorescence intensity (MFI)
 standard deviation. *, statistical significance compared to the results observed with the
isogenic parent strain.
FIG 6 Cytotoxicity of conditioned medium for primary osteoclasts. Pri-
mary bone marrow-derived murine osteoclasts were exposed to CM from
cultures of the indicated strains. After 12 h, viability was assessed by TRAP
staining, with the graph representing the results of quantitative analysis of
all replicates. (Inset) TRAP-positive multinucleated cells. *, statistical sig-
nificance compared to the results observed with the isogenic parent strain.
TABLE 1 Relative production of select proteins in LAC, UAMS-1, and
their isogenic sarA mutants
Protein
Avg no. of spectral countsa
LAC
LAC sarA
mutant UAMS-1
UAMS-1 sarA
mutant
Alpha toxin 1,019 117 0 0
PVL (LukF) 324 2,292 0 0
PVL (LukS) 229 1,458 0 0
LukD 104 576 0 0
LukE 23 3 0 0
1PSM 102 15 56 13
2PSM 32 0 0 0
3PSM 12 0 0 0
4PSM 112 5 64 14
Delta toxin 159 40 317 83
Spa 903 1 1,379 29
a Results reflect the average number of spectral counts from triplicate samples as
assessed by GeLC-MS/MS.
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mulation of PSMs may be a primary factor contributing to the re-
duced virulence of both LAC and UAMS-1 sarA mutants in our
model.
To address this, we used our murine osteomyelitis model to
compare each parent strain and its PSM mutants. The results
confirmed that eliminating the production of PSMs in LAC sig-
nificantly reduced both the reactive new bone formation and the
cortical bone destruction observed in thismodel (Fig. 10). In con-
trast, neither of these parameters was significantly reduced in
the UAMS-1 PSM mutant in comparison to that in the iso-
genic parent strain. Thus, while these results suggest that PSMs
play some role in the pathogenesis of acute, posttraumatic os-
teomyelitis even in strains like UAMS-1, they likely play amuch
more predominant role in defining USA300 strains like LAC. It
is important to note in this regard that while the results ob-
served with sarA mutants in vitro in the context of cytotoxicity
(Fig. 3 to 6) were consistent with those observed in vivo in the
overall context of bone remodeling (Fig. 2), this was not the
case with a UAMS-1 PSM mutant (Fig. 8 to 10). This may be
due to the fact that PSMs can be inactivated when bound by
host lipoproteins (37), an effect that would presumably be
more evident in a strain like UAMS-1 that produces PSMs at
relatively low levels.
The mechanistic basis for the role of PSMs in the pathogenesis
of osteomyelitis also remains undetermined, but they are known
to act as intracellular toxins that lyse osteoblasts, and this is par-
ticularly true for PSMs fromhypervirulent strains of S. aureus, like
LAC (5). PSMs have also been shown to induce the production of
interleukin-8 (27), which in turn can promote osteoclast differen-
tiation and activity (38). Taken together, these would presumably
have the effect of increasing bone destruction by decreasing osteo-
blast activity while increasing osteoclast activity. It is difficult to
envision how either would promote reactive bone formation, but
it is noteworthy that this occurred at distinct sites distal to the
inoculation site (Fig. 1). Together, these factors suggest the possi-
bility that reactive bone formation is a downstream effect arising
from the recruitment of osteoclasts to the site of infection and/or
the systemic inflammatory response.
Finally,while our results demonstrate an important role forPSMs
in the pathogenesis of osteomyelitis in LAC, they also suggest that
other virulence factors play an important role in defining both the
virulenceofUAMS-1and the attenuationof its isogenic sarAmutant.
For instance, the fact thatCMfromaUAMS-1PSMmutant culture
exhibitedmore cytotoxicity for primary osteoblasts than CM from a
LACPSMmutant culture (Fig. 9) suggests thatUAMS-1produces a
potentially relevant cytolytic factor that either is not produced by
LAC or is produced in reduced amounts relative to the amounts in
which it is produced by UAMS-1. Additionally, the fact that a
UAMS-1 sarA mutant was less cytotoxic than a LAC sarA mutant
(Fig. 3 to 6) suggests that the abundance of the relevant factor(s) is
decreased in a UAMS-1 sarAmutant.
One possibility is this regard are superantigens like TSST-1 and
those encodedwithin the enterotoxin gene cluster (egc), which are
produced by UAMS-1 but not LAC (39). However, while we did
not detect TSST-1 in our proteomics analysis for the reasons dis-
cussed above, mutation of sarA has been shown to result in an
increase in the production of TSST-1, albeit under in vitro condi-
tions (40). One other possibility that does meet these criteria is
protein A (Spa), which is present in both cell-associated and ex-
FIG 7 PSM levels assessed by GeLC-MS/MS. Black bars, amounts of the
indicated PSMs produced by LAC or UAMS-1; gray bars, amounts of the
indicated PSMs produced by the isogenic sarAmutants. *, statistically signifi-
cant difference for the indicated peptide compared to the amount of the same
peptide observed in the isogenic parent strain.
FIG 8 Cytotoxicity in established cell lines as a function of PSM produc-
tion. MC3T3-E1 or RAW 264.7 cells were exposed to CM from cultures of
LAC, UAMS-1 (U1), their isogenic psm mutants (psm), and comple-
mented psm mutants (psm
C). Viability was assessed after 24 h using
Invitrogen Live calcein-AM staining. Results of calcein-AM staining are
reported as the average mean fluorescence intensity (MFI) 
 standard
deviation. *, statistical significance compared to the results observed with
the isogenic parent strain; **, statistical significance compared to the re-
sults observed with the isogenic psm mutant.
FIG 9 Impact of PSMs on cytotoxicity for primary osteoblasts and osteoclasts.
Primary osteoblast cells were exposed to CM from cultures of the indicated
strains. Viability was assessed after 24 h using Invitrogen Live calcein-AM
staining. (Left) The results of calcein-AM staining are reported as the average
mean fluorescence intensity (MFI) 
 standard deviation. (Right) Primary
bone marrow-derived murine osteoclasts were exposed to CM from cultures
of the indicated strains. After 12 h, viability was assessed by TRAP staining,
with the graph representing the results of quantitative analysis of all replicates.
*, statistical significance compared to the results observed with the isogenic
parent strain in both cell types.
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tracellular forms (41, 42) and was previously shown to bind to
preosteoblastic cells via tumor necrosis factor alpha receptor 1,
resulting in apoptosis and, ultimately, bone loss (43). Thus, pro-
tein Awas present in increased amounts inUAMS-1 relative to the
amounts in LAC (Spa in Table 1) and could have contributed to
the virulence of UAMS-1, and elimination of PSM production in
UAMS-1 had comparatively little impact in this model. The fact
that the accumulation of Spa was reduced in a UAMS-1 sarAmu-
tant could also account for why mutation of sarA had a compara-
ble impact in both strains. At the same time, the generated sarA
mutants of both strains still caused bone destruction and new
bone formation to a degree that exceeded that observed with the
sham-treated controls (Fig. 2). This is potentially important be-
cause it implicates virulence factors whose abundance is not im-
pacted by mutation of sarA at the level of either their production
or their accumulation.
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